New York, New York 11101


Purpose:

The overarching plan for TOWER is to develop and test an algorithmic version of the Center for Disease Control Guidelines (CDCG) tailored for a specific primary care setting, the HIV primary care clinic. This CDCG intervention incorporates communication and implementation strategies tailored for the HIV primary care setting, and enabled with technology (an app for use by patients and EMR tools for providers).


Study summary:

However, according to a 2014 AHRQ report, there have been no studies evaluating the effectiveness of any prescription opioid risk mitigation strategies. Furthermore, due to ambiguity in some of the CDCG recommendations and the challenging nature of the patient-provider opioid conversation, the success of the CDCG may hinge on the manner in which it is implemented in individual care settings. Thus it is unclear what the true effect of the CDCG will be. The investigators believe that for the CDCG to have the greatest likelihood of achieving its goals of improving prescription opioid safety without causing unintended effects (e.g. exacerbation of pain, disruption of other aspects of care), its recommendations will need to be skillfully communicated. Furthermore, because of this "human element"and other sources of variability, documenting the effectiveness of the CDCG will require standardization of implementation. The overarching plan for TOWER is to develop and test an algorithmic version of the CDCG tailored for a specific primary care setting, the HIV primary care clinic. This CDCG intervention incorporates communication and implementation strategies tailored for the HIV primary care setting, and enabled with technology (an app for use by patients and EMR tools for providers). Achieving this goal has involved soliciting input from the HIV community using the method of Public Deliberation (PD) in the setting of two Citizen' s Panels, each with ~22 HIV-infected participants and lasting one day; and using the information obtained from the deliberative process to inform the development of the CDCG intervention. The investigators now plan to test the CDCG intervention for feasibility.


Criteria:

Inclusion Criteria: - Attending physician or advance practice provider in one of the Institute of Advanced Medicine (IAM) clinics - Designated PCP for at least 5 patients to whom he/she prescribes opioids - Willing and able to adhere to study procedures including randomization, and refraining from discussion of study procedures with other clinical staff or patients Exclusion Criteria: - Unwillingness to undergo randomization - Plans to leave IAM within the study period.


NCT ID:

NCT03669939


Primary Contact:

Principal Investigator
Jessica Robinson-Papp, MD
Icahn School of Medicine at Mount Sinai

Mary Catherine George, PhD
Phone: 212-241-0784
Email: mary-catherine.george@mssm.edu


Backup Contact:

Email: jessica.robinson-papp@mssm.edu
Jessica Robinson-Papp, MD
Phone: 212-241-8390


Location Contact:

New York, New York 11101
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.